These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 27621622)

  • 1. Development of TIMP1 magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infection.
    Atluri VS; Jayant RD; Pilakka-Kanthikeel S; Garcia G; Samikkannu T; Yndart A; Kaushik A; Nair M
    Int J Nanomedicine; 2016; 11():4287-98. PubMed ID: 27621622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat positively regulates synaptic plasticity genes expression and spine density in HIV infected neurons: role of nicotine in progression of HIV-associated neurocognitive disorder.
    Atluri VS; Pilakka-Kanthikeel S; Samikkannu T; Sagar V; Kurapati KR; Saxena SK; Yndart A; Raymond A; Ding H; Hernandez O; Nair MP
    Mol Brain; 2014 May; 7():37. PubMed ID: 24886748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy.
    Gill AJ; Kovacsics CE; Vance PJ; Collman RG; Kolson DL
    J Virol; 2015 Oct; 89(20):10656-67. PubMed ID: 26269184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted brain derived neurotropic factors (BDNF) delivery across the blood-brain barrier for neuro-protection using magnetic nano carriers: an in-vitro study.
    Pilakka-Kanthikeel S; Atluri VS; Sagar V; Saxena SK; Nair M
    PLoS One; 2013; 8(4):e62241. PubMed ID: 23653680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human synaptic plasticity gene expression profile and dendritic spine density changes in HIV-infected human CNS cells: role in HIV-associated neurocognitive disorders (HAND).
    Atluri VS; Kanthikeel SP; Reddy PV; Yndart A; Nair MP
    PLoS One; 2013; 8(4):e61399. PubMed ID: 23620748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel elvitegravir nanoformulation for drug delivery across the blood-brain barrier to achieve HIV-1 suppression in the CNS macrophages.
    Gong Y; Chowdhury P; Nagesh PKB; Rahman MA; Zhi K; Yallapu MM; Kumar S
    Sci Rep; 2020 Mar; 10(1):3835. PubMed ID: 32123217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Magnetic nanotherapeutics for dysregulated synaptic plasticity during neuroAIDS and drug abuse.
    Sagar V; Atluri VS; Pilakka-Kanthikeel S; Nair M
    Mol Brain; 2016 May; 9(1):57. PubMed ID: 27216740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of the immune system in HIV-associated neuroinflammation and neurocognitive implications.
    Hong S; Banks WA
    Brain Behav Immun; 2015 Mar; 45():1-12. PubMed ID: 25449672
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel nanoformulation to mitigate co-effects of drugs of abuse and HIV-1 infection: towards the treatment of NeuroAIDS.
    Jayant RD; Atluri VSR; Tiwari S; Pilakka-Kanthikeel S; Kaushik A; Yndart A; Nair M
    J Neurovirol; 2017 Aug; 23(4):603-614. PubMed ID: 28762183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy.
    Wächter C; Eiden LE; Naumann N; Depboylu C; Weihe E
    J Neuroinflammation; 2016 Oct; 13(1):272. PubMed ID: 27737697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Magnetic Nanoparticle and Exosomal Therapeutic (M-NEXT) Effects on HIV-Associated Neurotoxicity.
    Caobi A; Andre M; Miles J; Tomitaka A; Nikkhah-Moshaie R; Hernandez A; Nair M; Raymond AD
    Crit Rev Biomed Eng; 2020; 48(3):189-198. PubMed ID: 33389896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebral Vascular Toxicity of Antiretroviral Therapy.
    Bertrand L; Velichkovska M; Toborek M
    J Neuroimmune Pharmacol; 2021 Mar; 16(1):74-89. PubMed ID: 31209776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanoformulated Antiretrovirals for Penetration of the Central Nervous System: State of the Art.
    Fiandra L; Capetti A; Sorrentino L; Corsi F
    J Neuroimmune Pharmacol; 2017 Mar; 12(1):17-30. PubMed ID: 27832401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoparticle-mediated targeted delivery of antiretrovirals to the brain.
    Mahajan SD; Law WC; Aalinkeel R; Reynolds J; Nair BB; Yong KT; Roy I; Prasad PN; Schwartz SA
    Methods Enzymol; 2012; 509():41-60. PubMed ID: 22568900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for spermine oxidase as a mediator of reactive oxygen species production in HIV-Tat-induced neuronal toxicity.
    Capone C; Cervelli M; Angelucci E; Colasanti M; Macone A; Mariottini P; Persichini T
    Free Radic Biol Med; 2013 Oct; 63():99-107. PubMed ID: 23665428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced antiretroviral drug efficacy and concentration in HIV-infected microglia contributes to viral persistence in brain.
    Asahchop EL; Meziane O; Mamik MK; Chan WF; Branton WG; Resch L; Gill MJ; Haddad E; Guimond JV; Wainberg MA; Baker GB; Cohen EA; Power C
    Retrovirology; 2017 Oct; 14(1):47. PubMed ID: 29037245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain-Accumulating Nanoparticles for Assisting Astrocytes to Reduce Human Immunodeficiency Virus and Drug Abuse-Induced Neuroinflammation and Oxidative Stress.
    Surnar B; Shah AS; Park M; Kalathil AA; Kamran MZ; Ramirez Jaime R; Toborek M; Nair M; Kolishetti N; Dhar S
    ACS Nano; 2021 Oct; 15(10):15741-15753. PubMed ID: 34355558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients.
    Langford D; Marquie-Beck J; de Almeida S; Lazzaretto D; Letendre S; Grant I; McCutchan JA; Masliah E; Ellis RJ
    J Neurovirol; 2006 Apr; 12(2):100-7. PubMed ID: 16798671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of antiretroviral treatment on blood-brain barrier integrity and intrathecal immunoglobulin production in neuroasymptomatic HIV-1-infected patients.
    Abdulle S; Hagberg L; Gisslén M
    HIV Med; 2005 May; 6(3):164-9. PubMed ID: 15876282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.